PIN31 COST PER CYTOMEGALOVIRUS-ASSOCIATED DEATH AVERTED OF GANCICLOVIR AND VALGANCICLOVIR USE FOR PRE-EMPTIVE AND TREATMENT STRATEGIES IN ALLOGENEIC POSTTRANSPLANT RECIPIENTS
Abstract
Authors
P. Sangmala K. Tawinprai U. Bunworasate P. Niparuck S. Jaroenpatarapesaj P. Siri